Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study

BACKGROUND Peak incidence of rotavirus gastroenteritis is seen in infants between 6 and 24 months of age. We therefore aimed to assess the 2-year efficacy and safety of an oral live attenuated human rotavirus vaccine for prevention of severe gastroenteritis in infants. METHODS 15 183 healthy infants aged 6-13 weeks from ten Latin American countries randomly assigned in a 1 to 1 ratio to receive two oral doses of RIX4414 or placebo at about 2 and 4 months of age in a double-blind, placebo-controlled phase III study were followed up until about 2 years of age. Primary endpoint was vaccine efficacy from 2 weeks after dose two until 1 year of age. Treatment allocation was concealed from investigators and parents of participating infants. Efficacy follow-up for gastroenteritis episodes was undertaken from 2 weeks after dose two until about 2 years of age. Analysis was according to protocol. This study is registered with ClinicalTrials.gov, number NCT00140673 (eTrack444563-023). FINDINGS 897 infants were excluded from the according-to-protocol analysis. Fewer cases (p<0.0001) of severe rotavirus gastroenteritis were recorded for the combined 2-year period in the RIX4414 group (32 [0.4%] of 7205; 95% CI 0.3-0.6) than in the placebo group (161 [2.3%] of 7081; 1.9-2.6), resulting in a vaccine efficacy of 80.5% (71.3-87.1) to 82.1% (64.6-91.9) against wild-type G1, 77.5% (64.7-86.2) against pooled non-G1 strains, and 80.5% (67.9-88.8) against pooled non-G1 P[8] strains. Vaccine efficacy for hospital admission for rotavirus gastroenteritis was 83.0% (73.1-89.7) and for admission for diarrhoea of any cause was 39.3% (29.1-48.1). No cases of intussusception were reported during the second year of follow-up. INTERPRETATION Two doses of RIX4414 were effective against severe rotavirus gastroenteritis during the first 2 years of life in a Latin American setting. Inclusion of RIX4414 in routine paediatric immunisations should reduce the burden of rotavirus gastroenteritis worldwide.

[1]  R. Glass,et al.  The epidemiology of rotavirus diarrhea in Latin America. Anticipating rotavirus vaccines. , 2004, Revista panamericana de salud publica = Pan American journal of public health.

[2]  Y. Hoshino,et al.  Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine , 2005, Reviews in medical virology.

[3]  M. Estes,et al.  Anti-rotavirus G type-specific and isotype-specific antibodies in children with natural rotavirus infections. , 1994, The Journal of infectious diseases.

[4]  R. Glass,et al.  Serum antibody as a marker of protection against natural rotavirus infection and disease. , 2000, The Journal of infectious diseases.

[5]  J. Bines,et al.  Acute intussusception in infants and children as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation. , 2004, Vaccine.

[6]  D. Bernstein,et al.  Rotarix: development of a live attenuated monovalent human rotavirus vaccine. , 2006, Pediatric annals.

[7]  A. Walters,et al.  Restless Legs Syndrome: Prevalence and Impact in Children and Adolescents—The Peds REST Study , 2007, Pediatrics.

[8]  R. Glass,et al.  Rotavirus vaccines: current prospects and future challenges , 2006, The Lancet.

[9]  R. Glass,et al.  Rotavirus infection in infants as protection against subsequent infections. , 1996, The New England journal of medicine.

[10]  G. Marshall,et al.  Clinical and epidemiological aspects of rotavirus infection. , 2006, Pediatric annals.

[11]  L. Villa,et al.  Vaccines against rotavirus and human papillomavirus (HPV). , 2006, Jornal de pediatria.

[12]  A. C. Linhares,et al.  Vacinas contra rotavírus e papilomavírus humano (HPV) , 2006 .

[13]  A. Linhares,et al.  [Rotavirus infection in Brazil: epidemiology and challenges for its control]. , 2000, Cadernos de saude publica.

[14]  J. Bresee,et al.  Rotavirus vaccines and vaccination in Latin America. , 2000, Revista panamericana de salud publica = Pan American journal of public health.

[15]  R. Glass,et al.  Rotavirus and Severe Childhood Diarrhea , 2006, Emerging infectious diseases.

[16]  T. Vesikari,et al.  Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study , 2007, The Lancet.

[17]  G. Ruiz-Palacios,et al.  Dose Response and Efficacy of a Live, Attenuated Human Rotavirus Vaccine in Mexican Infants , 2007, Pediatrics.

[18]  T. Vesikari,et al.  Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. , 2006, The New England journal of medicine.

[19]  T. Breuer,et al.  Economic and health burden of rotavirus gastroenteritis for the 2003 birth cohort in eight Latin American and Caribbean countries. , 2007, Revista panamericana de salud publica = Pan American journal of public health.

[20]  Gillian M. Keating.  Rotavirus Vaccine RIX4414 (Rotarix™) , 2006, Paediatric drugs.

[21]  T. Vesikari,et al.  Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. , 1990, Scandinavian journal of infectious diseases.

[22]  R. Glass,et al.  Rotavirus Strain Surveillance in Latin America: A Review of the Last Nine Years , 2004, The Pediatric infectious disease journal.